With momentum building around combination approaches in IPF, this panel will explore how to design smarter strategies grounded in mechanistic complementarity, translatable models, and biomarker-driven patient selection.

Key Talking Points:

• Identifying orthogonal vs. redundant mechanisms to guide rational combination design
• Reassessing preclinical models to better evaluate multi-drug interactions, safety, and efficacy
• Using biomarkers and radiomics to refine patient stratification and predict response
• Defining when standard-of-care therapy isn’t enough and how to optimize add-on strategies for maximum impact